Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vascular Perfusion Solutions Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. ROGERS, ERIC JASON is the busiest examiner, currently handling 1 pending office action.
The distribution of 2 pending office actions across 2 distinct examiners indicates that each active case is being handled by a different individual. This lack of examiner overlap means that the company cannot rely on a single point of contact for its current docket. Additionally, the presence of 2 distinct art units suggests that the 2 pending office actions cover different technical aspects of the biotechnology field. Practitioners must develop separate prosecution strategies for each examiner, as the individual preferences of ROGERS, ERIC JASON will only apply to 1 pending office action. This decentralized structure for a small portfolio requires careful coordination to ensure consistent claim language across different examination groups. The involvement of 2 distinct examiners for the 2 pending office actions requires a diversified prosecution approach where each case is treated as a unique entity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18772620 | PORTABLE OXYGEN SOURCE WITH PERFUSION SYSTEM | ROGERS, ERIC JASON | — |
| 18335346 | TISSUE PERFUSION AND VIABILITY SENSING SYSTEM | VAN BUREN, LAUREN K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18772620 | PORTABLE OXYGEN SOURCE WITH PERFUSION SYSTEM | ROGERS, ERIC JASON | — |
| 18335346 | TISSUE PERFUSION AND VIABILITY SENSING SYSTEM | VAN BUREN, LAUREN K | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18772620 | PORTABLE OXYGEN SOURCE WITH PERFUSION SYSTEM | ROGERS, ERIC JASON | 1638 | §102§103§112 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18335346 | TISSUE PERFUSION AND VIABILITY SENSING SYSTEM | VAN BUREN, LAUREN K | 1655 | §102§103§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVascular Perfusion Solutions Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Eric Jason Rogers has the most, with 1 of Vascular Perfusion Solutions Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
